课题基金 / 基金详情

DEVELOPMENT OF SPLIT DAMID AS AN ALTERNATIVE METHODOLOGY TO CHROMATIN IMMUNOPRECI

DEVELOPMENT OF SPLIT DAMID AS AN ALTERNATIVE METHODOLOGY TO CHROMATIN IMMUNOPRECI
开发分裂 DAMID 作为染色质免疫分析的替代方法
批准号:
7815022
负责人:
RAPHAEL KOPAN
金额:
$50.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-08-31

项目摘要

项目成果

RAPHAEL KOPAN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):研究领域:(06)使能技术挑战主题:神经科学研究的新技术(06-MH-103)项目名称:Split-DamID作为染色质免疫沉淀的替代方法的开发项目摘要各种各样的遗传或药物诱导的精神健康障碍与转录因子的功能改变有关,无论是药物引起的还是基因缺陷引起的。 虽然我们知道,暴露于精神药物后,大脑中许多基因的表达模式会发生改变,但最终我们必须确定哪些基因直接被相关转录因子激活,以揭示表达层次结构并优先考虑可药用靶点。 鉴定这些“直接靶标”的进展缓慢,因为用于鉴定转录因子(染色质IP或ChIP)的直接靶标的传统方法昂贵、劳动密集且技术要求高。 最令人生畏的是,它们需要非常好的抗体和大量的起始材料,这在很大程度上限制了它们对培养细胞的使用。 为了提供一种避免这些问题的方法,我们优化了替代技术DamID的灵敏度和特异性,以广泛用于神经科学。 我们的解决方案(Split-DamID)依赖于我们成功将细菌DNA腺嘌呤甲基转移酶(Dam)分成N-末端(D)和C-末端(AM)的能力。 每一半都是不活跃的;然而,当与相互作用的转录因子融合时,这两个半体将仅在这些转录因子相互作用的结合位点处重建酶活性。 重建的Dam通过在任何转录因子的大多数同源结合位点附近发现的序列GAmTC中添加甲基(Am)来标记腺嘌呤(A)。 值得注意的是,这种表观遗传修饰从未在真核DNA中发现,似乎对细胞或生物体的生存没有影响。 该GAmTC标记允许通过用Dpn 1消化和衔接子介导的PCR从总DNA中分离转录因子结合的DNA,Dpn 1是一种仅抑制GAmTC位点处甲基化的DNA的酶。 当与Notch或Mef 2c融合时,我们已经成功地重建了Dam活性。 重要的是,我们已经观察到在重构与Notch融合的分裂-Dam的细胞中,已知Notch靶标相对于其他DNA片段的富集。 Split-DamID具有几个关键优势:与ChIP或DamID相比,信噪比大大提高;腺嘌呤甲基化永久标记融合蛋白结合的DNA,允许鉴定瞬时相互作用;标记DNA的回收与抗体可用性无关;并且通过衔接子介导的PCR扩增标记的DNA使其适合于与融合蛋白的内源表达水平一起工作,并且低表达量。起始材料的量。 此外,Spilt-DamID允许精确的空间和时间控制大坝重建。 我们建议用心理健康相关因子(Notch、DeltaFos B、CREB、NF B和Mef 2)和常见的转录辅激活因子(p300等)生成多个Split-Dam对,以仅在发生转录的位点重建Dam活性。 这些靶向载体、表达载体、细胞和动物将为研究人员创造一个资源,这些研究人员有兴趣在暴露于精神药物或携带已知影响人类行为的突变的动物模型中识别与精神健康有关的转录因子直接结合的位点。 我们将开发资源,允许对脑功能感兴趣的研究人员标记和识别与感兴趣的转录因子结合的关键靶基因(例如,涉及精神健康、癌症和神经科学中的其他转录驱动过程的那些)。 它们将控制标记发生的时间,使转录活性和行为精确相关。 与目前的技术相比,我们的新方法将适用于任何转录因子,并且只需要几只动物,因为该方法允许扩增回收的靶位点。 它应该允许快速表征涉及精神健康的大量转录因子,并促进识别因疾病或药物滥用而改变的治疗相关靶点。 此外,所有使用的试剂将从美国境内的公司获得,资源将通过美国的保管机构提供给社区。
英文摘要
DESCRIPTION (provided by applicant): Research Area: (06) Enabling Technologies Challenge topic: New technologies for neuroscience research (06-MH-103) Project Title: Development of Split-DamID as an alternative methodology to chromatin immunoprecipitation Project Abstract A wide variety of genetic or drug-induced mental health disorders have been linked to altered functions of transcription factors, be it drug-induced or caused by genetic defects. Although it is known that the expression patterns of many genes are altered in the brain after exposure to a psychotropic drug, ultimately we must determine which genes were directly activated by the relevant transcription factors to uncover the expression hierarchy and prioritize druggable targets. Progress towards identification of these "direct targets" has been slow since the traditional methods used to identify the immediate targets of a transcription factor (chromatin IP or ChIP) are expensive, labor-intensive and technically demanding. Most dauntingly, they require very good antibodies and a large amount of starting material, largely limiting their use to cells in culture. In order to provide an approach that avoids these issues, we have optimized the sensitivity and specificity of an alternative technology, DamID, for broad use in neuroscience. Our solution (Split-DamID) relies on our ability to successfully split the bacterial DNA adenine methyltransferase (Dam) into N-terminal (D) and C-terminal (AM) halves. Each half is inactive; however, when fused to interacting transcription factors, the halves will reconstitute enzymatic activity only at the binding sites where these transcription factors interact. The reconstituted Dam marks adenine (A) by addition of a methyl group (Am) in the sequence GAmTC found in proximity to most cognate binding sites of any transcription factor. It is important to note that this epigenetic modification is never found in eukaryotic DNA and appears to have no consequence to cellular or organism survival. This GAmTC mark allows isolation of the transcription factor bound DNA from total DNA through digestion with Dpn1, an enzyme that digests only DNA methylated at GAmTC sites, and adaptor mediated PCR. We have successfully reconstituted Dam activity when fused to Notch or Mef2c. Importantly, we have observed enrichment of known Notch targets over other DNA fragments in cells reconstituting split-Dam fused to Notch. Split-DamID has several key advantages: much improved signal to noise ratio compared with ChIP or DamID; adenine methylation indelibly marks DNA bound by the fusion protein, allowing identification of transient interactions; the recovery of marked DNA is independent of antibody availability; and the amplification of the marked DNA by adaptor mediated PCR makes it amenable to working with the endogenous expression level of the fusion protein and low amounts of starting material. Moreover, Spilt-DamID permits precise spatial and temporal control of Dam reconstitution. We propose to generate multiple Split-Dam pairs with mental health related factors (Notch, DeltaFosB, CREB, NF¿B, and Mef2) and common transcription co-activators (p300, others) to reconstitute Dam activity only at sites where transcription takes place. These targeting vectors, expression vectors, cells and animals will create a resource for investigators interested in identifying sites directly bound by transcription factors implicated in mental health in animal models exposed to psychotropic drugs or carrying a mutation known to affect behavior in humans. We will develop resources allowing investigators interested in brain function to mark and identify key target genes bound by transcription factors of interest (e.g., those involved in mental health, cancer, and other transcription-driven processes in neuroscience). They will have control over when the marking occur, enabling precise correlation of transcriptional activity and behavior. In contrast to the current technology, our novel method will work for any transcription factor and requires only a few animals since the method allows amplification of the recovered target sites. It should allow the rapid characterization of the vast array of transcription factors involved in mental health and facilitate identification of therapeutically relevant targets altered by disease or drug abuse. Additionally, all of the reagents used will be obtained from companies within the USA, and the resource will be made available to the community through American depositories.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Mechanism Regulating Renal Progenitor Aging
ASSESSING THE THERAPEUTIC WINDOW FOR FUTURE ANTI-NOTCH DIMERIZATION AGENTS
ASSESSING THE THERAPEUTIC WINDOW FOR FUTURE ANTI-NOTCH DIMERIZATION AGENTS
2012 Notch Signaling in Development, Regeneration & Disease Gordon Conference
  • 批准号:
    8334175
  • 项目类别:
  • 资助金额:
    $1.0万
  • 财政年份:
    2012
  • 负责人:
    RAPHAEL KOPAN
  • 依托单位:
海外基金